COMP <GO>
DGX vs JNJ // FREE CASH FLOW YIELD
Quest Diagnostics Incorporated (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: DGX 6
— JNJ 8
▲ FREE CASH FLOW YIELD LEADER: DGX
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
fcf-yield
4.88%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 67.90% | -34.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | 25.50% | -15.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 18.5x | -2.20 | DGX | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.88% | 2.97% | +1.91 | DGX | /fcf-yield <GO> |
| Operating Margin | 14.10% | 34.70% | -20.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 28.50% | -19.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 6.00% | +5.80 | DGX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.27% | 0.00% | +1.27 | DGX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.01 | 5.59 | -1.58 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | DGX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.3 | 60.4 | +7.98 | DGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.08 | -0.07 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 23.0x | +3.10 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.83B | $662.49B | -$634.67B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | JNJ REV | DGX GROSS % | JNJ GROSS % | DGX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $94.19B | 33.2% | 67.9% | $1.36B | $19.70B |
| FY 2024 | $9.87B | $88.82B | 32.9% | 69.1% | $909.0M | $19.84B |
| FY 2023 | $9.25B | $85.16B | 44.0% | 44.0% | $855.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
JNJ // BETA 1.08